Medirom Healthcare Ownership
| MRM Stock | USD 1.38 0.02 1.43% |
Shares in Circulation | First Issued 2017-12-31 | Previous Quarter 7.9 M | Current Value 5.9 M | Avarage Shares Outstanding 5 M | Quarterly Volatility 786.9 K |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medirom Healthcare Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. Medirom Stock Ownership Analysis
About 26.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.76. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Medirom Healthcare had not issued any dividends in recent years. MEDIROM Healthcare Technologies Inc. provides holistic healthcare services in Japan. MEDIROM Healthcare Technologies Inc. was incorporated in 2000 and is headquartered in Tokyo, Japan. MEDIROM Healthcare operates under Personal Services classification in the United States and is traded on NASDAQ Exchange. It employs 171 people. To find out more about Medirom Healthcare Technologies contact Kouji Eguchi at 81 3 6721 7364 or learn more at https://medirom.co.jp.Besides selling stocks to institutional investors, Medirom Healthcare also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Medirom Healthcare's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Medirom Healthcare's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Medirom Healthcare Quarterly Liabilities And Stockholders Equity |
|
About 26.0% of Medirom Healthcare Technologies are currently held by insiders. Unlike Medirom Healthcare's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Medirom Healthcare's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Medirom Healthcare's insider trades
Medirom Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Medirom Healthcare is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Medirom Healthcare Technologies backward and forwards among themselves. Medirom Healthcare's institutional investor refers to the entity that pools money to purchase Medirom Healthcare's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2025-03-31 | 98.3 K | Citadel Advisors Llc | 2025-03-31 | 67.4 K | Xtx Topco Ltd | 2025-03-31 | 14.1 K | Gamma Investing Llc | 2025-06-30 | 104 | Warberg Asset Management Llc | 2025-03-31 | 0.0 | Heights Capital Management Inc | 2025-03-31 | 0.0 | Virtu Financial Llc | 2024-12-31 | 0.0 | Bank Of America Corp | 2024-12-31 | 0.0 |
Medirom Healthcare Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Medirom Healthcare insiders, such as employees or executives, is commonly permitted as long as it does not rely on Medirom Healthcare's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Medirom Healthcare insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cohen Edward H over six months ago Disposition of 2500 shares by Cohen Edward H of Medirom Healthcare at 11.18 subject to Rule 16b-3 | ||
Cohen Edward H over a year ago Disposition of 2500 shares by Cohen Edward H of Medirom Healthcare at 9.78 subject to Rule 16b-3 |
Medirom Healthcare Outstanding Bonds
Medirom Healthcare issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Medirom Healthcare uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Medirom bonds can be classified according to their maturity, which is the date when Medirom Healthcare Technologies has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medirom Healthcare Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Medirom Healthcare. If investors know Medirom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Medirom Healthcare listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.278 | Earnings Share 0.19 | Revenue Per Share | Quarterly Revenue Growth 0.312 | Return On Assets |
The market value of Medirom Healthcare is measured differently than its book value, which is the value of Medirom that is recorded on the company's balance sheet. Investors also form their own opinion of Medirom Healthcare's value that differs from its market value or its book value, called intrinsic value, which is Medirom Healthcare's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Medirom Healthcare's market value can be influenced by many factors that don't directly affect Medirom Healthcare's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Medirom Healthcare's value and its price as these two are different measures arrived at by different means. Investors typically determine if Medirom Healthcare is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Medirom Healthcare's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.